Caplin Point Laboratories Ltd (CAPLIPOINT) is currently trading at 2,590.05 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.

Caplin Point Laboratories is an India‑headquartered pharmaceutical company focused on developing, manufacturing and exporting a broad portfolio of generic formulations and sterile injectables to Latin America, Africa and regulated markets including the US and EU through subsidiaries such as Caplin Steriles and regional distribution units. Management reports an active and expanding US ANDA pipeline with recent first‑cycle approvals for complex suspension injectables and ophthalmic emulsions, a growing US label business approaching ~$10 million since inception, and an expectation of several more ANDA approvals and launches across FY26–FY28. The company is mid‑way through a substantive capacity build‑out (Phase 3 injectable lines, ophthalmic, pre‑filled syringes and blow‑fill‑seal technology) plus a Vizag API plant for backward integration, positioning Caplin Point Laboratories to increase self‑reliance and reduce external API exposure over the medium term. Financially Caplin delivered steady growth with nine‑month revenue up ~10.6% YoY, PAT margin near 28.5%, strong free cash generation and INR 1,381 crore of cash and equivalents, enabling continued capex funding, selective inorganic bolt‑ons and a war chest for opportunistic acquisitions. Compliance and operational rigor are being institutionalized via video SOPs (visual SOPs) with planned AI governance and a filed patent, and the company has cleared recent EU GMP and Saudi FDA audits without critical observations, highlighting its regulatory readiness for expanded exports.

Over the past 52 weeks, Caplin Point Laboratories Ltd has traded between a low of ₹1,502.45 and a high of ₹2,874.00. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.

Caplin Point Laboratories Ltd has a market capitalization of approximately 20,939.32. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.

Caplin Point Laboratories Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 30.88 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.

Based on its market capitalization of 20,939.32 Cr, Caplin Point Laboratories Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.

Caplin Point Laboratories Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.

The Price-to-Earnings (PE) ratio of Caplin Point Laboratories Ltd is 30.88. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.

Caplin Point Laboratories has set September 18, 2026 as the record date for eligibility for the 35th AGM and the FY2025-26 final dividend, if declared.

Caplin Point reported consolidated net profit of ₹179.09 crore for Q1 FY27, up 18.8% from ₹150.76 crore in Q1 FY26.

For the quarter ended December 2025, consolidated sales rose 10.10% to ₹542.77 crore and net profit rose 17.93% to ₹163.88 crore.

Caplin Steriles received final USFDA approval for its ANDA for Calcium Gluconate Injection USP (100 mg/mL) in 10 mL, 50 mL and 100 mL vials.